Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Hematol Oncol ; 17(1): 63, 2024 Aug 07.
Artículo en Inglés | MEDLINE | ID: mdl-39113112

RESUMEN

Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal treatment, without adequate mycological evidence. Over the past years, wide use of antifungal prophylaxis resulted in decreased occurrence of IFD but has contributed to changes in the spectrum of fungal pathogens, revealing the occurrence of previously rare fungal genera causing breakthrough infections. The expanding spectrum of clinically relevant fungal pathogens required the implementation of screening approaches permitting broad rather than targeted fungus detection to support timely onset of pre-emptive antifungal treatment. To address this diagnostically important aspect in a prospective setting, we analyzed 935 serial peripheral blood (PB) samples from 195 pediatric and adult patients at high risk for IFD, involving individuals displaying febrile neutropenia during treatment of hematological malignancies or following allogeneic hematopoietic stem cell transplantation. Two different panfungal-PCR-screening methods combined with ensuing fungal genus identification by Sanger sequencing were employed. In the great majority of PB-specimens displaying fungal DNAemia, the findings were transient and revealed fungi commonly regarded as non-pathogenic or rarely pathogenic even in the highly immunocompromised patient setting. Hence, to adequately exploit the diagnostic potential of panfungal-PCR approaches for detecting IFD, particularly if caused by hitherto rarely observed fungal pathogens, it is necessary to confirm the findings by repeated testing and to identify the fungal genus present by ensuing analysis. If applied appropriately, panfungal-PCR-screening can help prevent unnecessary empirical therapy, and conversely, contribute to timely employment of effective pre-emptive antifungal treatment strategies.


Asunto(s)
ADN de Hongos , Neutropenia Febril , Huésped Inmunocomprometido , Humanos , Estudios Prospectivos , Adulto , Neutropenia Febril/microbiología , ADN de Hongos/análisis , Femenino , Masculino , Niño , Adolescente , Persona de Mediana Edad , Prevalencia , Adulto Joven , Anciano , Hongos/aislamiento & purificación , Hongos/genética , Neoplasias Hematológicas/complicaciones , Preescolar , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Infecciones Fúngicas Invasoras/epidemiología , Infecciones Fúngicas Invasoras/prevención & control , Infecciones Fúngicas Invasoras/etiología , Infecciones Fúngicas Invasoras/microbiología , Antifúngicos/uso terapéutico
2.
Am J Hematol ; 96(6): 719-726, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-33784434

RESUMEN

The importance of viral infections as a leading cause of morbidity and mortality is well documented in severely immunosuppressed patients undergoing allogeneic stem cell transplantation. By contrast, viral infections generally receive less attention in patients with malignant disorders undergoing chemotherapy, where the onset of neutropenic fever is mostly associated with bacterial or fungal infections, and screening for viral infections is not routinely performed. To address the occurrence of invasive viral infections in a clinical setting commonly associated with less pronounced immunosuppression, we have prospectively screened 237 febrile neutropenic episodes in pediatric (n = 77) and adult (n = 69) patients undergoing intensive chemotherapy, primarily for treatment of acute leukemia. Serial peripheral blood specimens were tested by RQ-PCR assays for the presence and quantity of the clinically relevant viruses CMV, EBV, HHV6 and HAdV, commonly reactivated in highly immunocompromised patients. Viremia was documented in 36 (15%) episodes investigated, including the detection of HHV6 (n = 14), EBV (n = 15), CMV (n = 6), or HAdV (n = 1). While low or intermediate levels of viremia (<104 virus copies/mL) were commonly associated with bacterial or fungal co-infection, viremia at higher levels (>104 copies/mL) was documented in patients without evidence for other infections, raising the possibility that at least in some instances the onset of fever may have been attributable to the virus detected. The observations suggest that viral infections, potentially resulting from reactivation, might also play a clinically relevant role in patients receiving chemotherapy for treatment of malignant neoplasms, and routine screening for viremia in this clinical setting might be warranted.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neutropenia Febril/epidemiología , Infecciones por Herpesviridae/epidemiología , Neoplasias/tratamiento farmacológico , Viremia/epidemiología , Adolescente , Adulto , Anciano , Aloinjertos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/etiología , Niño , Preescolar , Ensayos Clínicos como Asunto/estadística & datos numéricos , Terapia Combinada , Comorbilidad , Susceptibilidad a Enfermedades , Neutropenia Febril/etiología , Trasplante de Células Madre Hematopoyéticas , Herpesviridae/efectos de los fármacos , Herpesviridae/fisiología , Infecciones por Herpesviridae/etiología , Humanos , Huésped Inmunocomprometido , Lactante , Recién Nacido , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Micosis/epidemiología , Micosis/etiología , Neoplasias/epidemiología , Neoplasias/terapia , Estudios Prospectivos , Carga Viral , Viremia/etiología , Activación Viral/efectos de los fármacos , Activación Viral/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA